Effer-K

Description: Effer-K® 25 mEq TABLETS (Potassium Bicarbonate Effervescent Tablets for Oral Solution, USP) are intended for the preparation of an oral solution of potassium. Each tablet contains 2.5 g. potassium bicarbonate and 2.1 g. citric acid which in solution provides 25 mEq (978 mg) of elemental potassium as potassium citrate. Tablets also contain: SD flavors, microcrystalline cellulose, mineral oil, saccharine and talc. The orange tablets contain FD&C yellow No. 6 and FD&C yellow No, 6 lake. The lemon citrus tablets contain D&C yellow No. 10 and yellow No. 10 lake. The cherry berry tablets contain FD&C red No. 40 and FD&C red No. 40 lake. The unflavored tablets do not contain any natural or synthetic dyes, flavors or sweeteners.

Tablets are one inch in diameter round, flat face on both sides with large bevels. "EK-25" is imprinted on one side of the tablets. Each tablet is foil-pouched with the product description on one side of the pouch and the lot number, expiration and barcode on the other.

Potassium ion is the principal intracellular cation of most body tissues, whereas sodium ion is relatively low in concentration. In extracellular fluid the opposite exists, sodium ion being principal and potassium ion being low. The situation is maintained by an active membrane-bound enzyme (Na⁺K⁺ATPase). This potassium ion concentration gradient is essential to conduct nerve impulses in such specialized tissues as the brain, heart, and skeletal muscle; and in addition, to maintain normal renal function, acid-base balance, and various cellular metabolic functions. Elimination values are 90% renal and 10% fecal.

Potassium depletion may occur if the rate of potassium ion loss by renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium ion intake. Such depletion usually develops slowly as a consequence of prolonged therapy with oral diuretics, primary or secondary hyperaldosteronism, diabetic ketoacidosis, severe diarrhea, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Potassium depletion due to these causes is usually accompanied by a concomitant deficiency of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, mood or mental changes, nausea, vomiting, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and in advanced cases flaccid paralysis and/or impaired ability to concentrate urine.

1. For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis.
2. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassiumlosing nephropathy, and certain diarrheal states; long-term corticosteroid therapy.
3. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated.

Potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. Conditions predisposing to hyperkalemia include: chronic renal failure, acute metabolic acidosis, uncontrolled diabetes mellitus, esophageal compression or delayed gastric emptying or intestinal obstruction/stricture or peptic ulcer. Potassium supplements should be used with caution and only where medically indicated in patients with familial periodic paralysis, myotonia congenita or severe/complete heart block. IMPORTANT: Potassium supplements are contraindicated in patients receiving potassium-sparing diuretics (e.g. spironolactone, triamterene) since such use may produce severe hyperkalemia.

In patients with hyperkalemia and impaired mechanisms for excreting potassium the administration of potassium salts can produce hyperkalemia and cardiac arrest. This occurs most commonly in patients given potassium by the intravenous route but may also occur in patients given potassium orally. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic.

The use of potassium salts in patients with chronic renal disease, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustment.

Note: There is no conclusive evidence that potassium supplements lower blood pressure in hypertensive patients.

The diagnosis of potassium depletion is ordinarily made by demonstrating hypokalemia in a patient with a clinical history suggesting some cause for potassium depletion. In interpreting the serum potassium level, the physician should bear in mind that acute alkalosis per se can produce hypokalemia in the absence of a deficit in total body potassium, while acute acidosis per se can increase the serum potassium concentration into the normal range even in the presence of a reduced total body potassium. The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease, or acidosis, requires careful attention to acid-base balance and appropriate monitoring of serum electrolytes, the electrocardiogram, and the clinical status of the patient.

One of the most severe adverse effects is hyperkalemia (see Contraindications, Warnings and Overdosage). The most common adverse reactions to oral potassium salts are nausea, vomiting, abdominal discomfort, and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by diluting the preparation further, taking the dose with meals, or reducing the dose. Skin rash has been reported rarely.

The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired or if potassium is administered too rapidly intravenously, potentially fatal hyperkalemia can result (see Contraindications and Warnings). It is important to recognize that initally hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, depression of S-T segment, and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest.

Treatment measures for hyperkalemia include the elimination of foods and medications containing potassium and potassium-sparing diuretics, as well as ACE inhibitors, beta blocking agents, NSAIDs, heparin, and cyclosporine. In cases of life-threatening hyperkalemia, treatment measures may include: (1) intravenous administration of 300 to 500 ml/hr of 10% dextrose solution containing 10-20 units of insulin per 1,000 ml; (2) correction of acidosis, if present, with intravenous sodium bicarbonate; (3) use of exchange resins, hemodialysis, or peritoneal dialysis; (4) administration of a calcium salt to antagonize the cardiotoxic effects in patients whose electrocardiograms show appropriate characteristics, and who are not receiving digitalis glycosides; and (5) maintenance of a high urine output in suitable patients.

In treating hyperkalemia, it should be recalled that in patients who have been stabilized on digitalis, rapid lowering of serum potassium can produce digitalis toxicity.

Dosage and Administration: Adults- One Effer-K^® flavored tablet, (Orange, Lemon Citrus or Cherry Berry) each containing 25 mEq (978 mg) of potassium, completely dissolved in 4 ounces of cold or ice water, 1 to 4 times daily, depending on the requirement of the patient. For Effer-K^® unflavored tablets (each containing 25 mEq (978 mg) of potassium) we recommend completely dissolving one tablet in 12 to 16 ounces of cold juice of the patient's choice.

NOTE: It is suggested that any effervescent potassium tablets be taken with meals and sipped slowly over a 5 to 10 minute period.

NDC 51801-007-30
30 Tablets

Effer-K^® 25 mEq Tablets

POTASSIUM BICARBONATE EFFERVESCENT TABLETS
FOR ORAL SOLUTION, USP

Each Tablet contains 25mEq (978 mg) of Potassium

Unflavored (Dissolve in 12-16 ounces of juice)
Rx Only

nomax inc

PRINCIPAL DISPLAY PANEL - 30 Tablet Pouch Carton - Unflavored

NDC 51801-001-30
30 Tablets

Effer-K^® 25 mEq Tablets

POTASSIUM BICARBONATE EFFERVESCENT TABLETS
FOR ORAL SOLUTION, USP

Each Tablet contains 25mEq (978 mg) of Potassium

Orange Flavored
Rx Only

nomax inc

NDC 51801-005-30
30 Tablets

Effer-K^® 25 mEq Tablets

POTASSIUM BICARBONATE EFFERVESCENT TABLETS
FOR ORAL SOLUTION, USP

Each Tablet contains 25mEq (978 mg) of Potassium

Lemon Citrus Flavored
Rx Only

nomax inc

PRINCIPAL DISPLAY PANEL - 30 Tablet Pouch Carton - Lemon

NDC 51801-006-30
30 Tablets

Effer-K^® 25 mEq Tablets

POTASSIUM BICARBONATE EFFERVESCENT TABLETS
FOR ORAL SOLUTION, USP

Each Tablet contains 25mEq (978 mg) of Potassium

Cherry Berry Flavored
Rx Only

nomax inc

PRINCIPAL DISPLAY PANEL - 30 Tablet Pouch Carton - Cherry